Clinical trial · Observational
Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer
Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer
NCT00176579CI-TRIAL-00005360completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Measuring bone mineral density may help doctors predict whether prostate cancer will come back. It may also help the study of prostate cancer in the future. PURPOSE: This clinical trial is studying whether bone mineral density affects cancer recurrence in patients with early stage prostate cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteoporosis | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dual x-ray absorptiometry | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Bone mineral density
- timeFrame
- Baseline
- description
- DXA scan will be done after patient signs consent and eligibilty is confirmed
- measure
- Prostate Specific Antigen
- timeFrame
- Baseline, every 6 months for 3 years
- description
- PSA will be measured to look for biochemical recurrence of prostate cancer
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Biopsy-confirmed early stage prostate cancer * Disease localized within the capsule * No evidence of regional or distant spread (i.e., T1-2, N0, M0 disease) * A cohort of patients must have undergone a prior radical prostatectomy * Prostate specific antigen \< 12 ng/mL * Gleason score ≥ 6 PATIENT CHARACTERISTICS: * Creatinine clearance ≤ 2.0 mg/dL * No Paget's disease * No hyperthyroidism or hypothyroidism * No Cushing's disease * No chronic liver disease * No major health problems that would cause a significant reduction in mobility or activities of daily living PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior bisphosphonates, thyroxin, or calcitonin * No prior agents that suppress PSA levels (e.g., finasteride) * No prior androgen or estrogen therapy * More than 12 months since prior glucocorticoids * More than 12 months since prior herbal supplements that are known to lower PSA levels
References
Publications (0)
Data not yet available
No reference posted for this study.